Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study

M. Lommatzsch (Rostock, Germany), S. Korn (Mainz, Germany), T. Plate (Wedel, Germany), T. Grund (Wedel, Germany), H. Watz (Grosshansdorf, Germany)

Source: Virtual Congress 2021 – Advances in asthma treatment

Session: Advances in asthma treatment
Session type: E-poster
Number: 3538

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Lommatzsch (Rostock, Germany), S. Korn (Mainz, Germany), T. Plate (Wedel, Germany), T. Grund (Wedel, Germany), H. Watz (Grosshansdorf, Germany). Late Breaking Abstract - Early benefits in patient-reported outcomes (PROs) and physical activity (PA) in patients with severe eosinophilic asthma (SEA) treated with benralizumab: interim analysis of the imPROve Asthma study. 3538

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014
Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016
X-Tab: Non-interventional study to assess patient-related mid-term outcomes of omalizumab therapy in severe allergic asthmatic patients Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016
Factors influencing to HRQOL of patients with mild to moderate persistent asthma in Japan; sub-analysis of GAIA study Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Discordant symptom severity in COPD: The PHAROAH study Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015
Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Loneliness and lack of social support severely influences patients’ quality of life. Secondary findings from our focusgroup study in asthma and COPD patients Source: International Congress 2016 – Best abstracts in COPD management Year: 2016
Quality of life (QOL) and pulmonary rehabilitation (PRP) : Functional correlates in asthma and COPD outpatients Source: International Congress 2018 – Asthma and drugs Year: 2018
Agreement between patient-reported and chart documented outcomes: Case study in COPD Source: Annual Congress 2013 –Lung function tests to monitor airway diseases Year: 2013
LATE-BREAKING ABSTRACT: Early identification of responders to reslizumab at 16 weeks using an algorithm derived from the pivotal clinical studies of severe eosinophilic asthma (SEA) patients Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities Year: 2016
Observational study to characterise 24-hour COPD symptoms: Interim analysis of ASSESS Source: Annual Congress 2013 –Monitoring symptoms and quality of life Year: 2013
The CAN questionnaire relates differences in the quality of life of asthmatics (PAQL) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
Late Breaking Abstract - Compare outcomes between COPD patients treated with tiotropium/olodaterol (TIO/OLO) and umeclidium/vilanterol (UMEC/VI) Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020
REG study: Real-life, longitudinal ICS adherence patterns in a UK asthma population Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015
A randomised controlled trial of cognitive behavioural therapy (CBT) delivered by respiratory nurses to reduce anxiety in chronic obstructive pulmonary disease (COPD). (Trial registration - ISCRCTN55206395) Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016
Late Breaking Abstract: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry (BB) Source: Annual Congress 2010 - Asthma and COPD: understanding through monitoring Year: 2010
The control of asthma in real life: Baseline evaluation of a long-term study Source: International Congress 2016 – Monitoring airway diseases with clinical tools Year: 2016
Neuropsychological and Quality of life (QoL) assessment in children with severe asthma (SA) and moderate persistent asthma (MPA): a case-control study Source: International Congress 2018 – Insights in primary ciliary dyskinesia, asthma and lung function testing Year: 2018